SEC Form 4 · accession 0001209191-17-041857
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul W. Hoelscher
Officer — EVP, CFO
Period of report
Jun 23, 2017
Accepted (ET)
Jun 26, 2017 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jun 23, 2017 | M | 20,000 | — | A | 84,135 | D | |
| Ordinary Shares | Jun 23, 2017 | F | 9,140 | $11.73 | D | 74,995 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jun 23, 2017 | M | 20,000 | D | — | — | Ordinary Shares | 20,000 | 20,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Includes 1,428 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program.
- F3The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014).